All Eleven Director Nominees Elected to the Board at
Annual Meeting of Shareholders
LAVAL, Quebec, June 15, 2016 /PRNewswire/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today
announced that its Board of Directors has appointed Thomas W. Ross, Sr. as its lead independent
director. Mr. Ross, who has been a member of Valeant's Board
since March 8, 2016, serves on the
Board's Nominating and Corporate Governance Committee and is
Chairperson of its Conduct and Compliance Committee.
"I am delighted that Tom will serve Valeant in this important
role," said Joseph C. Papa, chairman
and chief executive officer. "Tom's contributions to the Board have
been invaluable, and I believe the Company will continue to benefit
greatly from his insights and expertise as we move Valeant
forward."
"I am pleased to expand my service to Valeant as its lead
independent director," said Mr. Ross. "The Board is very pleased
with our new CEO and Chairman, Mr. Papa, and we all share with Joe
and the management team, a deep commitment to working with
Valeant's strong assets and personnel to launch a new chapter in
the Company's history."
Following today's Annual Meeting of Shareholders, three new
independent directors were elected to Valeant's Board, including:
Dr. Argeris N. Karabelas, Russel C.
Robertson and Dr. Amy B.
Wechsler. Eight directors were re-elected -- Mr. Ross,
William A. Ackman, Dr. Frederic Eshelman, Stephen Fraidin, D.
Robert Hale, Robert A.
Ingram, Robert N. Power and
Joseph C. Papa. In the past
year, Valeant has significantly refreshed its Board, adding nine
new directors and expanding the number of independent directors to
10 out of 11. The detailed results of the vote for the election of
directors are set out below:
Name
|
|
For
|
|
Withheld
|
|
Broker
Non-Votes
|
|
|
|
|
|
|
|
|
|
William A.
Ackman
|
|
198,528,445
|
|
2,803,967
|
|
61,983,675
|
|
Dr. Frederic N.
Eshelman
|
|
197,044,996
|
|
3,787,416
|
|
61,983,675
|
|
Stephen
Fraidin
|
|
198,643,367
|
|
2,189,045
|
|
61,983,675
|
|
D. Robert
Hale
|
|
196,991,641
|
|
3,840,771
|
|
61,983,675
|
|
Robert A.
Ingram
|
|
185,459,606
|
|
15,372,806
|
|
61,983,675
|
|
Dr. Argeris (Jerry)
N. Karabelas
|
|
198,470,956
|
|
2,361,456
|
|
61,983,675
|
|
Joseph C.
Papa
|
|
195,388,625
|
|
5,443,787
|
|
61,983,675
|
|
Robert N.
Power
|
|
187,463,060
|
|
13,369,352
|
|
61,983,675
|
|
Russel C.
Robertson
|
|
198,700,104
|
|
2,132,308
|
|
61,983,675
|
|
Thomas W. Ross,
Sr.
|
|
198,249,663
|
|
2,582,749
|
|
61,983,675
|
|
Amy B. Wechsler,
M.D.
|
|
198,488,329
|
|
2,344,083
|
|
61,983,675
|
|
At the annual meeting, shareholders also approved the
non-binding advisory vote on named executive officer compensation
as disclosed in the proxy statement and appointed
PricewaterhouseCoopers LLP as the Company's independent registered
public accounting firm until the close of the Company's 2017 annual
meeting of shareholders.
The final vote tabulation on all matters voted on at today's
meeting will be reported to the U.S. Securities and Exchange
Commission on a current report on Form 8-K and such report will be
made available on the Company's web site at www.valeant.com.
Thomas W. Ross, Sr. is President
Emeritus of the 17-campus University of North
Carolina having served as President from 2011-2016. He
currently serves as the Sanford Distinguished Fellow in Public
Policy at the Duke University Sanford
School of Public Policy and as a Professor of Public Law and
Government at the UNC Chapel Hill School of Government. On
July 1, 2016, Mr. Ross will assume
the role of President of the Volker Alliance in New York. Prior to becoming President of the
UNC System, Mr. Ross served as President of Davidson College, executive director of the Z.
Smith Reynolds Foundation, director of the North Carolina
Administrative Office of the Courts, a Superior Court judge, chief
of staff to a U. S. Congressman, a member of a Greensboro, NC law firm and as an Assistant
Professor of Public Law and Government at UNC-Chapel Hill's School of Government. Mr.
Ross holds a bachelor's degree in political science from
Davidson College and graduated with
honors from the UNC-Chapel Hill School of Law. Mr. Ross
currently serves several boards and has received numerous awards
and accolades for his public service and professional
achievements.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorders,
eye health, neurology and branded generics. More information about
Valeant can be found at www.valeant.com.
Contact Information:
Laurie W. Little
laurie.little@valeant.com
or
Elif McDonald
elif.mcdonald@valeant.com
514-856-3855
877-281-6642 (toll free)
Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080
Logo -
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-appoints-thomas-w-ross-sr-lead-independent-director-300284964.html
SOURCE Valeant Pharmaceuticals International, Inc.